Medistep Healthcare limited IPO
Medistep Healthcare Limited, incorporated on June 05, 2023, is a Public Limited Company operating in the pharmaceutical and healthcare sector. The company is engaged in the manufacturing and trading of pharmaceuticals, nutraceuticals, surgical products, and intimate care and hygiene products. A key milestone in its early growth was the acquisition of M/s MG Pharma, a proprietorship firm owned by Ms. Prajapati Hetalben Girdharilal, enabling the seamless integration of MG Pharma’s business into the Medistep brand.
Business Model
Medistep Healthcare Limited has developed a robust and scalable business model built around two core verticals:
a) Manufacturing Division
1. DRYSTEP: In-house production of sanitary pads, contributing to the intimate care and hygiene segment.
2. VITASTEP-Z: Production of nutraceutical energy powders, addressing the growing demand for wellness and health supplements.
b) Trading & Distribution Division
The company is actively engaged in the trading and distribution of:
i) Pharmaceutical products
ii) Nutraceuticals
iii) Surgical products
iv) Intimate care and hygiene products
Medistep’s operations are supported by a strong distribution network that ensures timely and consistent product availability across markets. The company is committed to providing quality-assured products that comply with safety and regulatory standards.
Competitive Strengths
1. Experienced Promoters and Management Team: The leadership team brings deep domain expertise and entrepreneurial vision, having successfully guided the company’s growth and operational efficiency. Their active involvement ensures strategic direction and daily business execution.
2. Scalable Business Model: Medistep’s business model is customer-driven and order-based, focusing on product quality, cost optimization, and market expansion. The company leverages economies of scale and marketing expertise to grow sustainably.
3. Wide Product Portfolio: The company offers a comprehensive range of healthcare products, including its own manufactured brands (DRYSTEP & VITASTEP-Z) and a diverse portfolio of traded goods across pharmaceutical, nutraceutical, surgical, and hygiene categories.
Objects of the Medistep Healthcare limited IPO:
Medistep Healthcare limited IPO Details:
Open Date: | Aug 08 2025 |
Close Date: | Aug 12 2025 |
Total Shares: | 37,44,000 |
Face Value: | ₹ 10 Per Equity Share |
Issue Type: | Fixed Price |
Issue Size: | 16.10 Cr. |
Lot Size: | 1500 Shares |
Issue Price: | ₹ 43 Per Equity Share |
Listing At: | NSE Emerge |
Promoters And Management:
Financials of Medistep Healthcare limited IPO:
Metric | FY25 | FY24 | FY23 |
Total Revenue (₹ Lakhs) | 4,965.48 | 3,161.51 | 2,764.68 |
EBITDA (₹ Lakhs) | 559.74 | 395.61 | 133.91 |
PAT (₹ Lakhs) | 414.42 | 291.35 | 92.1 |
RoNW (%) | 29.06% | 44.44% | 131.24% |
RoCE (%) | 38.91% | 59.10% | 109.62% |
PAT Margin | 8.35% | 9.22% | 3.33% |
Comparison With Peers:
Company | CMP | EPS | P/E | RoNW | PAT (₹ Lakhs) |
Medistep | ₹43 | 4.01 | 13.85 | 24.62% | 414.42 |
Fabino Enterprises | ₹26 | 0.29 | 91 | 2.85% | 0.06 |
Achyut Healthcare | ₹4.18 | 0.55 | 180 | 1.77% | 0.55 |
Recommendation on Medistep Healthcare limited IPO:
Lead Manager of Medistep Healthcare limited IPO:
Registrar of Medistep Healthcare limited IPO:
Discussion on Medistep Healthcare limited IPO:
1 Comment
Leave a Reply
You must be logged in to post a comment.
Medistep Healthcare is a very small company with a post-IPO market cap of just ₹60 crore, raising ₹16 crore through its IPO—of which ₹12 crore is earmarked for working capital and ₹50 lakh for capex. Until FY24, the company was mainly engaged in trading pharma products like sanitary pads and energy powders, operating much like a small distributor. It has recently entered manufacturing, but the scale remains modest. In FY25, it posted ₹50 crore in revenue and ₹4 crore in PAT, with no debt on its books. While the IPO is priced at a reasonable P/E of ~13x, there’s no clear business moat or competitive edge. Given the micro-cap nature and absence of a scalable model, skipping this IPO may not result in any major loss. However, the small size could help manage listing momentum. Conservative investors may prefer to avoid, while high-risk takers can track post-listing behavior.